Human EIF3A/EIF3/eIF3-p170 ORF/cDNA clone-Adenovirus plasmid (NM_003750.2)

Cat. No.: pGMAD000160
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days

Pre-made Human EIF3A/EIF3/eIF3-p170 adenoviral expression plasmid for EIF3A adenovirus packaging, EIF3A adenovirus.

Our GM-Adenovirus vector is optimized with the GMVC-modified Adeasy adenovirus packaging system. Find more about the GMVC-modified adenovirus packaging system.

pdf Datasheet
pdf MSDS
pdf Terms of Use
Purchase
Shipping fee: Limited-time free
For payment issues, contact us.


Product Description

Catalog ID pGMAD000160
Gene Name EIF3A
Accession Number NM_003750.2
Gene ID 8661
Species Human
Product Type Adenovirus plasmid (overexpression)
Insert Length 4149 bp
Gene Alias EIF3,eIF3-p170,eIF3-theta,EIF3S10,P167,p180,p185,TIF32
Fluorescent Reporter GFP
Mammalian Cell Selection Null
Fusion Tag 3xflag (C-Terminal)
Promoter EF1
Resistance Amplicin
ORF Nucleotide Sequence ATGCCGGCCTATTTTCAGAGGCCGGAAAATGCCCTCAAACGCGCCAACGAATTTCTTGAGGTTGGCAAAAAGCAGCCTGCTCTGGATGTTCTTTATGATGTTATGAAAAGTAAAAAACATAGAACATGGCAAAAGATACACGAACCAATTATGTTGAAATACTTGGAACTTTGCGTGGATCTTCGCAAGAGCCACTTGGCAAAGGAGGGGTTATACCAGTATAAGAACATTTGTCAACAGGTGAACATAAAATCTCTGGAGGATGTTGTTAGGGCATATTTGAAAATGGCAGAGGAAAAAACTGAAGCTGCTAAAGAAGAATCTCAGCAGATGGTCTTAGATATAGAGGATCTAGATAATATTCAAACTCCTGAGAGTGTTCTCCTAAGTGCTGTAAGTGGTGAAGACACTCAGGATCGTACTGACAGATTACTTTTAACTCCATGGGTTAAATTCCTGTGGGAGTCTTACAGGCAGTGTTTGGACCTTCTTAGAAACAATTCTAGAGTAGAGCGCCTGTACCATGATATTGCCCAGCAAGCTTTCAAATTCTGCCTCCAATACACGCGTAAGGCTGAATTCCGTAAACTGTGTGACAATTTGAGAATGCACTTATCGCAGATTCAGCGCCACCATAACCAAAGTACGGCAATCAATCTTAATAATCCAGAGAGCCAGTCCATGCATTTGGAAACCAGACTTGTTCAGCTGGACAGTGCTATCAGCATGGAATTGTGGCAGGAAGCATTCAAAGCTGTGGAAGATATTCACGGGCTATTCTCCTTGTCTAAAAAACCACCTAAACCTCAGTTGATGGCAAATTACTATAACAAAGTCTCAACTGTGTTTTGGAAATCTGGAAATGCTCTTTTTCATGCATCTACACTCCATCGTCTTTACCATCTCTCTAGAGAAATGAGAAAGAATCTCACACAAGATGAGATGCAAAGAATGTCTACTAGAGTCCTTTTAGCCACTCTTTCCATCCCTATTACTCCTGAGCGTACGGATATTGCTCGACTTCTGGATATGGATGGCATTATAGTTGAAAAACAGCGTCGCCTTGCAACACTACTAGGTCTTCAAGCCCCACCGACACGAATTGGCCTTATTAATGATATGGTCAGATTTAATGTACTACAATATGTTGTCCCAGAAGTGAAAGACCTTTACAATTGGCTTGAAGTAGAATTTAACCCATTAAAACTCTGTGAGCGAGTCACAAAGGTTCTAAATTGGGTTAGGGAACAACCTGAAAAGGAACCGGAATTGCAGCAGTATGTGCCACAACTGCAAAACAACACCATCCTCCGCCTTCTGCAGCAGGTGTCACAGATTTATCAGAGCATTGAGTTTTCTCGTTTGACTTCTTTGGTTCCTTTTGTTGATGCTTTCCAACTGGAACGGGCCATAGTAGATGCAGCCAGGCATTGCGACTTGCAGGTTCGTATTGATCACACTTCTCGGACCCTGAGTTTTGGATCTGATTTGAATTATGCTACTCGAGAAGATGCTCCGATTGGTCCTCATTTGCAAAGCATGCCTTCAGAGCAGATAAGAAACCAGCTGACAGCCATGTCCTCAGTACTTGCAAAAGCACTTGAAGTCATTAAACCAGCTCATATACTGCAAGAGAAAGAAGAACAGCATCAGTTGGCTGTCACTGCATACCTTAAAAATTCACGAAAAGAGCACCAGCGGATCCTGGCTCGCCGCCAGACAATTGAGGAGAGAAAAGAGCGCCTTGAGAGTCTGAATATTCAGCGTGAGAAAGAAGAATTGGAACAGAGGGAAGCTGAACTCCAGAAAGTGCGGAAGGCTGAGGAAGAGAGGCTGCGCCAGGAAGCAAAGGAGAGAGAGAAGGAGCGTATCTTACAGGAACATGAACAAATCAAAAAGAAAACTGTCCGAGAGCGTTTGGAGCAGATCAAGAAAACAGAACTGGGTGCCAAAGCATTCAAAGATATTGATATTGAAGACCTTGAGGAATTGGATCCAGATTTTATCATGGCTAAACAGGTTGAACAACTGGAGAAAGAAAAGAAAGAACTTCAAGAACGCCTAAAGAATCAAGAAAAGAAGATTGACTATTTTGAAAGAGCCAAACGTTTGGAAGAAATTCCTTTGATAAAGAGCGCTTACGAGGAACAGAGAATTAAAGACATGGATCTGTGGGAGCAACAAGAGGAAGAAAGAATTACTACAATGCAGCTAGAACGTGAAAAGGCTCTTGAACATAAGAATCGAATGTCACGAATGCTTGAAGACAGAGATTTATTCGTAATGCGACTCAAAGCTGCACGGCAGTCTGTTTATGAGGAAAAACTTAAACAGTTTGAAGAGCGATTAGCAGAAGAAAGGCATAATCGATTGGAAGAACGGAAAAGGCAGCGTAAAGAAGAACGCAGGATAACATACTATAGAGAAAAAGAAGAGGAGGAGCAGAGAAGGGCAGAAGAACAAATGCTAAAAGAGCGGGAAGAGAGAGAGCGCGCCGAACGAGCAAAACGCGAGGAAGAGCTACGAGAGTATCAGGAGCGGGTGAAGAAATTAGAAGAAGTGGAAAGGAAAAAACGCCAAAGGGAGTTGGAAATTGAAGAACGAGAACGGCGTAGAGAGGAAGAGAGAAGACTTGGCGATAGTTCCCTTTCTAGAAAGGACTCTCGTTGGGGAGATAGAGATTCAGAAGGCACCTGGAGAAAAGGACCTGAAGCAGATTCTGAGTGGAGAAGAGGCCCGCCAGAGAAGGAGTGGAGACGTGGAGAAGGGCGAGATGAGGACAGGTCTCATAGAAGAGATGAAGAGCGGCCCCGGCGTCTGGGGGATGATGAAGATAGAGAGCCCTCTCTTAGACCAGACGATGATCGGGTTCCCCGGCGTGGCATGGATGATGACAGAGGCCCTAGACGTGGTCCTGAGGAAGATAGGTTCTCTCGTCGTGGGGCAGACGATGACCGGCCTTCCTGGCGTAACACAGATGATGACAGGCCTCCCAGACGAATTGCCGATGAAGACAGGGGAAACTGGCGTCATGCGGATGATGACAGACCACCTAGACGAGGACTGGATGAGGACAGAGGAAGCTGGCGAACAGCTGATGAGGACAGAGGACCAAGACGTGGGATGGATGATGACCGGGGGCCGAGGCGAGGAGGCGCTGATGATGAGCGATCATCCTGGCGTAATGCTGATGATGACCGGGGTCCCAGGCGAGGGTTGGATGATGATCGGGGTCCCAGGCGAGGCATGGATGATGACCGGGGTCCCAGGCGAGGCATGGATGATGACCGGGGTCCCAGGCGAGGCATGGATGATGACCGGGGTCCCAGGCGAGGGTTGGATGATGATCGAGGACCTTGGAGGAACGCCGATGATGACAGAATTCCCAGGCGTGGTGCAGAGGATGACAGGGGCCCTTGGAGAAACATGGATGATGATCGCCTTTCAAGACGTGCTGATGATGATCGGTTTCCCAGACGGGGTGATGACTCAAGACCTGGTCCTTGGAGACCATTAGTCAAGCCAGGTGGATGGAGAGAGAAAGAAAAAGCCAGAGAGGAGAGCTGGGGTCCACCTCGAGAATCAAGGCCATCAGAAGAACGTGAATGGGACAGAGAAAAAGAAAGGGACAGAGATAATCAAGATCGGGAGGAGAATGACAAGGACCCTGAGAGAGAAAGGGACAGAGAGAGAGATGTGGATCGAGAGGATCGCTTCAGAAGACCTAGGGATGAAGGTGGCTGGAGAAGAGGACCAGCTGAGGAATCTTCAAGCTGGAGAGACTCAAGTCGCCGGGACGATAGGGATAGGGATGACCGTCGCCGTGAGAGGGATGACCGGCGTGATCTAAGAGAAAGACGAGATCTAAGAGACGACAGGGACCGAAGAGGACCTCCACTCAGATCAGAACGTGAAGAAGTAAGTTCTTGGAGACGTGCTGATGACAGGAAAGATGACCGGGTGGAAGAGCGGGACCCTCCTCGTCGAGTTCCTCCCCCAGCTCTTTCAAGAGACCGAGAAAGAGACCGAGACCGAGAAAGAGAAGGTGAAAAAGAGAAGGCCTCATGGAGAGCTGAGAAAGATAGGGAATCTCTCCGTCGTACTAAAAATGAGACTGATGAAGATGGATGGACCACAGTACGACGTTAA
ORF Protein Sequence MPAYFQRPENALKRANEFLEVGKKQPALDVLYDVMKSKKHRTWQKIHEPIMLKYLELCVDLRKSHLAKEGLYQYKNICQQVNIKSLEDVVRAYLKMAEEKTEAAKEESQQMVLDIEDLDNIQTPESVLLSAVSGEDTQDRTDRLLLTPWVKFLWESYRQCLDLLRNNSRVERLYHDIAQQAFKFCLQYTRKAEFRKLCDNLRMHLSQIQRHHNQSTAINLNNPESQSMHLETRLVQLDSAISMELWQEAFKAVEDIHGLFSLSKKPPKPQLMANYYNKVSTVFWKSGNALFHASTLHRLYHLSREMRKNLTQDEMQRMSTRVLLATLSIPITPERTDIARLLDMDGIIVEKQRRLATLLGLQAPPTRIGLINDMVRFNVLQYVVPEVKDLYNWLEVEFNPLKLCERVTKVLNWVREQPEKEPELQQYVPQLQNNTILRLLQQVSQIYQSIEFSRLTSLVPFVDAFQLERAIVDAARHCDLQVRIDHTSRTLSFGSDLNYATREDAPIGPHLQSMPSEQIRNQLTAMSSVLAKALEVIKPAHILQEKEEQHQLAVTAYLKNSRKEHQRILARRQTIEERKERLESLNIQREKEELEQREAELQKVRKAEEERLRQEAKEREKERILQEHEQIKKKTVRERLEQIKKTELGAKAFKDIDIEDLEELDPDFIMAKQVEQLEKEKKELQERLKNQEKKIDYFERAKRLEEIPLIKSAYEEQRIKDMDLWEQQEEERITTMQLEREKALEHKNRMSRMLEDRDLFVMRLKAARQSVYEEKLKQFEERLAEERHNRLEERKRQRKEERRITYYREKEEEEQRRAEEQMLKEREERERAERAKREEELREYQERVKKLEEVERKKRQRELEIEERERRREEERRLGDSSLSRKDSRWGDRDSEGTWRKGPEADSEWRRGPPEKEWRRGEGRDEDRSHRRDEERPRRLGDDEDREPSLRPDDDRVPRRGMDDDRGPRRGPEEDRFSRRGADDDRPSWRNTDDDRPPRRIADEDRGNWRHADDDRPPRRGLDEDRGSWRTADEDRGPRRGMDDDRGPRRGGADDERSSWRNADDDRGPRRGLDDDRGPRRGMDDDRGPRRGMDDDRGPRRGMDDDRGPRRGLDDDRGPWRNADDDRIPRRGAEDDRGPWRNMDDDRLSRRADDDRFPRRGDDSRPGPWRPLVKPGGWREKEKAREESWGPPRESRPSEEREWDREKERDRDNQDREENDKDPERERDRERDVDREDRFRRPRDEGGWRRGPAEESSSWRDSSRRDDRDRDDRRRERDDRRDLRERRDLRDDRDRRGPPLRSEREEVSSWRRADDRKDDRVEERDPPRRVPPPALSRDRERDRDREREGEKEKASWRAEKDRESLRRTKNETDEDGWTTVRR

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    ORF Viral Vector vGMAD000160 Human EIF3A Adenovirus particle




    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.